Replimune Group, Inc. (REPL)
15.50
-0.10
(-0.64%)
USD |
NASDAQ |
Aug 28, 16:00
15.44
-0.06
(-0.39%)
After-Hours: 20:00
Replimune Group Cash from Operations (Quarterly) : -75.73M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -75.73M |
| March 31, 2026 | -56.16M |
| December 31, 2025 | -65.96M |
| September 30, 2025 | -81.21M |
| June 30, 2025 | -77.02M |
| March 31, 2025 | -53.73M |
| December 31, 2024 | -50.71M |
| September 30, 2024 | -38.64M |
| June 30, 2024 | -49.17M |
| March 31, 2024 | -46.17M |
| December 31, 2023 | -47.12M |
| September 30, 2023 | -43.59M |
| June 30, 2023 | -48.59M |
| March 31, 2023 | -32.80M |
| December 31, 2022 | -28.59M |
| September 30, 2022 | -33.21M |
| June 30, 2022 | -33.46M |
| Date | Value |
|---|---|
| March 31, 2022 | -22.56M |
| December 31, 2021 | -18.35M |
| September 30, 2021 | -22.96M |
| June 30, 2021 | -18.31M |
| March 31, 2021 | -16.13M |
| December 31, 2020 | -12.99M |
| September 30, 2020 | -17.18M |
| June 30, 2020 | -15.09M |
| March 31, 2020 | -11.26M |
| December 31, 2019 | -15.74M |
| September 30, 2019 | -19.97M |
| June 30, 2019 | -13.58M |
| March 31, 2019 | -6.033M |
| December 31, 2018 | -6.103M |
| September 30, 2018 | -6.383M |
| June 30, 2018 | -6.859M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Kalaris Therapeutics, Inc. | -11.43M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 49.99M |
| Cash from Financing (Quarterly) | 0.80M |
| Free Cash Flow | -280.54M |
| Free Cash Flow Per Share (Quarterly) | -0.7819 |
| Free Cash Flow to Equity (Quarterly) | -76.12M |
| Free Cash Flow to Firm (Quarterly) | -72.66M |
| Free Cash Flow Yield | -19.91% |